AU2014341862A1 - Compositions and methods for administration of an enzyme to a subject's airway - Google Patents

Compositions and methods for administration of an enzyme to a subject's airway Download PDF

Info

Publication number
AU2014341862A1
AU2014341862A1 AU2014341862A AU2014341862A AU2014341862A1 AU 2014341862 A1 AU2014341862 A1 AU 2014341862A1 AU 2014341862 A AU2014341862 A AU 2014341862A AU 2014341862 A AU2014341862 A AU 2014341862A AU 2014341862 A1 AU2014341862 A1 AU 2014341862A1
Authority
AU
Australia
Prior art keywords
composition
plasminogen activator
solution
subject
scupa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014341862A
Other languages
English (en)
Inventor
Steven Idell
Robert O. Williams Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53005414&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014341862(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2014341862A1 publication Critical patent/AU2014341862A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2014341862A 2013-11-04 2014-11-04 Compositions and methods for administration of an enzyme to a subject's airway Abandoned AU2014341862A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899739P 2013-11-04 2013-11-04
US61/899,739 2013-11-04
PCT/US2014/063784 WO2015066664A2 (en) 2013-11-04 2014-11-04 Compositions and methods for administration of an enzyme to a subject's airway

Publications (1)

Publication Number Publication Date
AU2014341862A1 true AU2014341862A1 (en) 2016-05-19

Family

ID=53005414

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014341862A Abandoned AU2014341862A1 (en) 2013-11-04 2014-11-04 Compositions and methods for administration of an enzyme to a subject's airway

Country Status (11)

Country Link
US (2) US20160279209A1 (https=)
EP (1) EP3065705A4 (https=)
JP (1) JP2016535782A (https=)
KR (1) KR20160078986A (https=)
CN (1) CN105764488A (https=)
AU (1) AU2014341862A1 (https=)
CA (1) CA2928759A1 (https=)
CL (1) CL2016001062A1 (https=)
MX (1) MX2016005720A (https=)
PE (1) PE20160789A1 (https=)
WO (1) WO2015066664A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110201144B (zh) 2013-03-15 2024-01-02 得克萨斯州大学系统董事会 用Nutlin-3a和肽抑制肺纤维化
EP3849580A4 (en) 2018-09-10 2022-06-15 Lung Therapeutics, Inc. MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THEIR USE IN THE TREATMENT OF FIBROSIS
WO2021180068A1 (zh) * 2020-03-09 2021-09-16 泰伦基国际有限公司 一种治疗2019新型冠状病毒引发疾病的方法和药物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4790305A (en) * 1986-06-23 1988-12-13 The Johns Hopkins University Medication delivery system
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
US5302390A (en) 1987-07-01 1994-04-12 Beecham Group Plc Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
US5531219A (en) 1994-11-04 1996-07-02 Alliance Pharmaceutical Corp. Use of liquid fluorocarbons to facilitate pulmonary drug delivery
AU3765897A (en) * 1996-08-14 1998-03-06 Jurgen Brodersen Gram Use of a plasminogen activator for the treatment of pulmonary disorders
US20030113271A1 (en) * 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
JP2005518274A (ja) * 2001-12-21 2005-06-23 エンバイロスクラブ テクノロジーズ コーポレイション マンガン酸化物の前処理および再生
US20050036951A1 (en) * 2003-01-09 2005-02-17 Arizeke Pharmaceuticals, Inc. Methods of treating lung diseases
US20050169908A1 (en) 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20060198940A1 (en) 2005-03-04 2006-09-07 Mcmorrow David Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance
US20070157931A1 (en) 2005-07-11 2007-07-12 Richard Parker System and method for optimized delivery of an aerosol to the respiratory tract
DK1962869T3 (da) * 2005-12-21 2013-06-24 Solaeromed Inc Behandling af luftvejssygdomme
SI22865A (sl) 2008-09-25 2010-03-31 Univerza@V@Ljubljani Peptid uroaktivin kot aktivator encima urokinaze
AU2009319772A1 (en) * 2008-11-26 2010-06-03 Centocor Research & Development, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by SERPINE2
DE102009031274A1 (de) * 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
WO2013029627A1 (en) * 2011-08-29 2013-03-07 Trifoilium Aps Compositions and methods for treating or preventing radiation- or chemotherapy-induced pulmonary dysfunction

Also Published As

Publication number Publication date
JP2016535782A (ja) 2016-11-17
CN105764488A (zh) 2016-07-13
US11033611B2 (en) 2021-06-15
US20160279209A1 (en) 2016-09-29
EP3065705A2 (en) 2016-09-14
CA2928759A1 (en) 2015-05-07
EP3065705A4 (en) 2017-10-18
MX2016005720A (es) 2016-11-25
WO2015066664A3 (en) 2015-09-17
KR20160078986A (ko) 2016-07-05
US20190255157A1 (en) 2019-08-22
CL2016001062A1 (es) 2017-01-13
WO2015066664A2 (en) 2015-05-07
PE20160789A1 (es) 2016-08-17

Similar Documents

Publication Publication Date Title
US11033611B2 (en) Compositions and methods for administration of an enzyme to a subject's airway
CN104203267A (zh) 用于治疗流感和副流感患者的方法、化合物和组合物
JP6397984B2 (ja) 乾燥粉末ペプチド医薬
WO2022009081A1 (en) Drug for use against the novel coronavirus disease, covid-19
JP2007524607A (ja) 凝固因子の吸入による血友病処置
JP2007524607A6 (ja) 凝固因子の吸入による血友病処置
US20130274171A1 (en) Trefoil factors (tff) for the treatment of chronic pulmonary diseases
US20230044025A1 (en) System and method of treating or preventing respiratory failure with aerosolized collagenase
US7807639B2 (en) Methods for preventing and treating local tracheal, bronchial or alveolar bleeding or hemoptysis
KR102664833B1 (ko) 나파모스타트 또는 카모스타트를 포함하는 흡입용 제제
JP2025011148A (ja) ウイルス性肺炎を治療する方法及び薬剤
US20180140547A1 (en) Compositions and methods for administration of an enzyme to a subject's airway
WO2020185826A1 (en) Compositions and methods for protecting type 2 alveolar epithelial cells (aec2)
RU2737799C1 (ru) Ингаляционный гексапептид для лечения респираторных заболеваний, связанных с интерлейкином-6
RU2496516C2 (ru) Введение в дыхательные пути ингибитора тканевого фактора при воспалительных состояниях, поражающих дыхательные пути
Vanbever Optimization of dry powder aerosols for systemic drug delivery
Abdalaziz et al. Formulation strategy for hydroxychloroquine as inhaler dosage from as a potential for COVID-19 treatment
KR20090110782A (ko) 폐 내부 영역에 대한 흡입 투여 또는 점적 투여 대상 활성물질의 담체로서 부분 불소치환 알칸의 사용
ZA200702428B (en) Methods for treating local trachéal, bronchial or alveolar bleeding or hemoptysis
MX2007016372A (es) Administracion a las vias respiratorias de la proteina c activada en condiciones inflamatorias que afectan el tracto respiratorio
WO2014071005A1 (en) Methods and compositions using neuroprotective steroids and thrombolytic agents

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period